Masimo Corporation

Valuation Analysis

About the Company

Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet

Masimo Corporation Stock at a Glance

Masimo Corporation (MASI) is currently trading at $179.95 with a market capitalization of $9.4B. The trailing P/E ratio stands at 44.43x, with a forward P/E of 26.84x. The 52-week range spans from $125.94 to $179.99; the current price is 0% below the yearly high. Year-over-year revenue growth stands at +8.5%. The net profit margin stands at 4.9%.

💰 Dividend

Masimo Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

3 analysts rate Masimo Corporation (MASI) on consensus: Hold. The average price target is $180.00, implying +0.03% from the current price. Analyst price targets range from $180.00 to $180.00.

Masimo Corporation: The Investment Case in Detail

Masimo Corporation (MASI) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 61.63%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

The Bear Case

With a net margin of just 4.9%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

At a PEG of 4.83, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 26.61x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 26.84x is meaningfully below the trailing 44.43x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 99.9% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to market-like volatility, elevated short interest (7.34%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Masimo Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.